Locations:

Using VAD in Single Ventricle as Long-Term Bridge to Transplant in Newborn

Innovative care sustains baby with complex heart disease

650×450-PediMag-ventricular-assist-device

By Gerard Boyle, MD, and Hani Najm, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A bridge to transplantation can require as much or more clinical innovation than the transplantation itself.

Such was the case with one newborn at Cleveland Clinic who had a complex form of congenital heart disease, making conventional repair impossible and survival until transplantation unlikely. In this case study, we discuss the patient’s months-long wait for a heart transplant and the innovative care that kept her alive.

Complex congenital heart disease

The patient was born with pulmonary atresia with an intact septum (hypoplastic right ventricle). She had patent ductus arteriosus (PDA), a duct between her aorta and pulmonary artery that supplied her lungs.

Prostaglandin initially helped keep the ductus open while the patient awaited a permanent repair. However, a BT shunt became necessary to maintain the flow of blood to her lungs longer term.

In addition to these heart defects, the patient also had right ventricle-dependent coronary circulation. Her heart was supplied not by normal coronary arteries but by connections inside her (abnormally small) right ventricle.

Following the insertion of the BT shunt, and because of her dependency on blood from the right ventricle, she was not able to sustain good ventricular function. She was placed on ECMO and listed for heart transplant.

We feared that ECMO would not keep her alive long enough to wait for a transplant — or that she would not be weanable from it due to her right ventricle dependency. ECMO would suffice for only one week to 10 days, certainly no more than two weeks.

Advertisement

Using VAD in duct-dependent circulation

Knowing that the patient’s lungs were normal, we needed to replace only her ventricular function. We put her on a long-term ventricular assist device (VAD), an extracorporeal centrifugal pump without an oxygenator.

Because she had duct-dependent circulation, we attached the VAD by injecting into the descending aorta, beyond the ductus arteriosus. This prevented less-oxygenated blood from the VAD being pumped into the aorta. By bypassing the ductus, her heart continued to pump higher-oxygenated blood to itself and her brain, while the VAD pumped less-oxygenated blood to the rest of her body.

This was acceptable because a newborn’s lower body can live with less oxygen. Our solution allowed us to maintain an oxygen saturation of 90 percent to the patient’s upper body and a saturation of 50 to 60 percent to the lower body.

An alternative to heparin for infants on VAD

Significant anticoagulation is required for patients on this type of VAD. Heparin is standard, yet it is not without concern when used in infants.

Frequent partial thromboplastin time (PTT) tests are required — several per day. Each test requires a large volume of blood, and recurring tests often necessitate blood transfusion. Blood transfusion can create complications for patients preparing for transplant as exposure to transfusions can alert the infants immune system (sensitize it) to possible donor organs and thereby increase the risk of rejection.

In addition, for unknown reasons, the PTT test is often unreliable in infants. It is not uncommon to see blood clots in the VAD of patients whom we thought were sufficiently anticoagulated. However, the PTT test is somehow more reliable for patients taking bivalirudin. More reliability means fewer tests are needed, which means less blood loss and fewer transfusions.

Advertisement

For these reasons, the patient received bivalirudin, instead of heparin, which kept her sufficiently anticoagulated with no harmful effects. This approach is relatively new and is just beginning to be acknowledged at other medical centers.

Post-transplant remarks

At three months of age, the patient had a heart transplant.

Now at 13 months, she has recovered all organ function, although she has a tracheostomy and remains on a ventilator. She has begun breathing on her own for several hours per day and soon will have the tracheostomy removed. No transplant rejection has been detected. She has started to stand and appears to be developing normally. She is quite social, interactive and playful.

This is a remarkable outcome given her degree of illness. Survival to transplant had been unlikely, yet several novel treatments helped us overcome the complexity of her condition and sustain her long enough to locate an organ match.

With modified techniques, it is feasible to employ VAD long-term in an infant with right ventricle-dependent coronary circulation and duct dependency.

Dr. Boyle is Medical Director of Pediatric Heart Failure and Transplant Services at Cleveland Clinic. Dr. Najm is Chair of Pediatric and Congenital Heart Surgery at Cleveland Clinic.

Advertisement

Related Articles

axial image of the human chest showing the heart and other organs

How Imaging Can Guide Smarter Aortic Valve and Root Decisions

New review proposes a multimodality framework for matching patients to procedures

color cardiac echo next to model of a bulging aorta

Distinctive CME on Valve Imaging and Connective Tissue Disorders on Tap for March 2027

In-depth live symposia in Florida and Cleveland feature interdisciplinary experts from around the nation

yellow and red illustration of blood cells moving through a blood vessel

First-in-Human Data Show One siRNA Can Lower Both LDL-C and Triglycerides

Early results for ARO-DIMER-PA point to a more streamlined way to treat mixed hyperlipidemia

blood vessel on top of a DNA double helix

CRISPR-Cas9 Gene Editing Therapy Safely Slashes Severely Elevated Triglycerides in Early Trial

Findings support further studies of potential one-time treatment strategy

two side-by-side medical illustrations with red trend line overlays

Lipoprotein(a) Reduction With Pelacarsen Has No Impact on Cardiac Events, Lp(a)HORIZON Finds

But unexpected results are ‘not the end of the story’ for Lp(a) lowering, investigators say

stylized heart and lungs with text overlay

Outcome Updates in Adult Cardiac Surgery, Ischemic Heart Disease and Vascular Disease

A scannable snapshot of recent volumes and results

illustration of aortic arch after stent graft repair

Evolving Strategies in Aortic Arch Repair (Podcast)

Earlier detection is reshaping timing and safety of these increasingly common surgeries

illustrated human gut with microbes and an overlay of a rhythm tracing

TMAO Shown to Be a Modifiable Risk Factor for Atrial Fibrillation

Bench-to-bedside study identifies mechanism and potential therapeutic target

Ad